← Back to Search

Anti-viral

Toward Elimination of Hepatitis C Virus (HCV): A Pilot Study (ELIMINATEC Trial)

Phase 4
Waitlist Available
Led By Ronald Nahass, MD
Research Sponsored by Id Care
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 year
Awards & highlights
All Individual Drugs Already Approved
Approved for 20 Other Conditions
Drug Has Already Been Approved
Pivotal Trial
No Placebo-Only Group

Summary

To demonstrate that colocation treatment of substance use disorder and Hepatitis C infection concurrently while proving addiction counselling will achieve increased duration of sobriety and elimination of Hepatitis C virus in study participants.

Eligible Conditions
  • Hepatitis C
  • Heroin Addiction

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 year for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Cure rate of Hepatitis C Infection
Secondary study objectives
Hepatitis C Reinfection Rate
Sobriety from Drug Use

Awards & Highlights

All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
Approved for 20 Other Conditions
This treatment demonstrated efficacy for 20 other conditions.
Drug Has Already Been Approved
The FDA has already approved this drug, and is just seeking more data.
Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Open Label Treatment ArmExperimental Treatment1 Intervention
Treatment arm using Glecaprevir-pibrentasvir for treatment of all patients

Find a Location

Who is running the clinical trial?

AbbVieIndustry Sponsor
1,040 Previous Clinical Trials
523,549 Total Patients Enrolled
110 Trials studying Hepatitis C
32,802 Patients Enrolled for Hepatitis C
Id CareLead Sponsor
Ronald Nahass, MDPrincipal InvestigatorId Care
~4 spots leftby Jan 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top